company background image
1XT logo

Xintela DB:1XT Stock Report

Last Price

€0.023

Market Cap

€23.3m

7D

3.5%

1Y

80.0%

Updated

16 Mar, 2025

Data

Company Financials

1XT Stock Overview

A biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. More details

1XT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Xintela AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Xintela
Historical stock prices
Current Share PriceSEK 0.023
52 Week HighSEK 0.044
52 Week LowSEK 0.0086
Beta1.94
1 Month Change4.46%
3 Month Change62.50%
1 Year Change80.00%
3 Year Change-85.73%
5 Year Change-91.73%
Change since IPO-92.17%

Recent News & Updates

Recent updates

Shareholder Returns

1XTDE BiotechsDE Market
7D3.5%3.1%-0.5%
1Y80.0%-6.0%15.5%

Return vs Industry: 1XT exceeded the German Biotechs industry which returned -5.8% over the past year.

Return vs Market: 1XT exceeded the German Market which returned 15.5% over the past year.

Price Volatility

Is 1XT's price volatile compared to industry and market?
1XT volatility
1XT Average Weekly Movement30.1%
Biotechs Industry Average Movement9.3%
Market Average Movement5.3%
10% most volatile stocks in DE Market12.0%
10% least volatile stocks in DE Market2.8%

Stable Share Price: 1XT's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 1XT's weekly volatility has decreased from 40% to 30% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
200921Evy Lundgren-Åkerlundwww.xintela.se

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company’s stem cell products include XSTEM that is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indications; and EQSTEM, which is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG10, which are in preclinical study for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.

Xintela AB (publ) Fundamentals Summary

How do Xintela's earnings and revenue compare to its market cap?
1XT fundamental statistics
Market cap€23.32m
Earnings (TTM)-€3.56m
Revenue (TTM)€382.40k

61.0x

P/S Ratio

-6.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1XT income statement (TTM)
RevenueSEK 4.22m
Cost of RevenueSEK 0
Gross ProfitSEK 4.22m
Other ExpensesSEK 43.41m
Earnings-SEK 39.19m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.059
Gross Margin100.00%
Net Profit Margin-929.77%
Debt/Equity Ratio0%

How did 1XT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/16 08:38
End of Day Share Price 2025/03/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Xintela AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.